Welcome!

News Feed Item

The Pharmaceutical Market: UK

NEW YORK, Nov. 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pharmaceutical Market: UK

http://www.reportlinker.com/p0203096/The-Pharmaceutical-Market-UK.html#u...

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 1

Snapshot: Strategic Espicom Analysis 2

Snapshot: Key Data Projections3

MACROENVIRONMENT 4

POLITICAL 4

ECONOMIC5

Projections 5

LEGAL6

EU Patent Protection & Intellectual Property Rights 6

Proposal for Unitary Patent 6

EU Supplementary Protection Certificates6

EU Data Exclusivity6

DEMOGRAPHIC 7

Projections 7

Demographic Indicators8

Births 8

Deaths 8

Infant Deaths 8

Life Expectancy at Birth 8

EPIDEMIOLOGY 9

DISEASE BURDEN 9

Leading Causes of Mortality9

DISEASE PREVALENCE10

Communicable Diseases 10

HIV/AIDS 10

Non-Communicable Diseases 11

Cancer 11

Diabetes 11

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12

EU DIRECTIVE12

Cross-Border Healthcare Directive 12

ORGANISATION 12

Performance 12

Structure 13

Department of Health 14

Strategic Health Authorities 14

Primary Care Trusts 14

Acute Trusts 14

NHS Foundation Trusts 14

NHS Care Trusts 15

Ambulance Trusts 15

Care Quality Commission 15

EXPENDITURE 17

Projections 17

NHS Budget 18

Private Healthcare 18

INFRASTRUCTURE 19

Hospital Infrastructure19

Private Hospital Operators19

BMI Healthcare 19

HCA International 19

Netcare 19

NHS Trusts 20

Nuffield Health 20

Partnership Health Group (PHG) 20

Ramsay Healthcare20

Spire Healthcare 20

Ambulatory Infrastructure21

SERVICES 21

Hospital Inpatient Services 21

Outpatient Services22

WORKFORCE 22

Projections 22

Physicians 23

Nurses 23

Dentists 24

Pharmacists 24

REGULATORY AFFAIRS 25

EU REGULATORY AUTHORITY 25

NATIONAL AUTHORITIES 25

MARKETING REGISTRATION 26

EU Marketing Registration26

Centralised Procedure 26

National Procedures 27

IMPORT REGULATIONS 27

Parallel Trade 27

PROMOTION 28

Advertising 28

PRICING & REIMBURSEMENT 29

EU NETWORKING MEETING 29

NM CAPR29

PRICING 29

PPRS Reforms 29

Patient Access Schemes 30

Prescription Charges 31

REIMBURSEMENT 31

DISTRIBUTION CHANNELS 34

EU DIRECTIVE 34

Falsified Medicines Directive34

DRUG WHOLESALING 34

Association of Wholesalers 34

BAPW34

Leading Wholesalers 35

AAH Pharmaceuticals 35

Alliance Healthcare35

DRUG RETAILING 36

Association of Independent Pharmacies 36

Numark36

Association of Community Pharmacies36

NPA 36

Leading Pharmacy Chains 37

Alliance Boots 37

Lloydspharmacy 37

Superdrug 37

MARKET ANALYSIS 38

SIZE 38

Projections 38

Historical Figures 40

Current Structure 41

PRODUCT DEVELOPMENT 49

EU Programmes49

Horizon 2020 49

IMI 49

National Research & Development 49

MANUFACTURING 52

TRADE53

Exports 53

Imports 56

Balance of Trade 60

COMPETITION 61

TRADE ASSOCIATIONS 61

ABPI 61

COMPANY INTELLIGENCE 62

AstraZeneca62

Eisai62

Eli Lilly 62

GlaxoSmithKline 62

MSD63

Novartis 63

Pfizer 64

ProStrakan64

Shire Pharmaceuticals 65

ViiV Healthcare 65

Competitive Strategies65

GLOBAL COMPANY INTELLIGENCE 66

AstraZeneca66

Company Overview 66

Financial Performance66

Product Portfolio 67

R&D Strategy 69

Manufacturing Capabilities 71

Outlook 71

GlaxoSmithKline 72

Company Overview 72

Financial Performance72

Product Portfolio 73

R&D Strategy 75

Manufacturing Capabilities 76

Outlook 76

Shire 77

Company Overview 77

Financial Performance78

Product Portfolio 79

R&D Strategy 80

Manufacturing Capabilities 81

OTC PHARMACEUTICALS 82

REGULATION 82

Marketing Registration 82

Labelling 82

MARKET SIZE 83

COMPETITION 84

Trade Association84

PAGB 84

GENERIC PHARMACEUTICALS 85

REGULATION 85

EU Marketing Registration85

Pricing & Reimbursement 85

Generic Substitution Plans are Scrapped 85

Unbranded Generic Pricing 85

2005 Generics Reimbursement Scheme 86

MARKET SIZE 87

COMPETITION 90

Trade Association90

BGMA90

Company Intelligence 90

Actavis 90

Bristol Laboratories90

Dr Reddy's 91

Kent Pharmaceuticals 91

Pfizer 91

Rosemont Pharmaceuticals 91

Teva Pharmaceuticals 91

Winthrop Pharmaceuticals 92

Wockhardt 92

BIOLOGICS & BIOSIMILARS 93

REGULATION 93

EU Approval Process 93

EU Regulation of Biosimilars 93

EMA Guideline Documents94

Draft Biosimilar Concept Paper94

Biosimilar mAb Guideline 94

Biosimilars Approved in the EU 95

National Regulation 95

NICE Approves First Biosimilar for NHS Use95

PRODUCT DEVELOPMENT 96

Cancer Research 96

Stem Cell Research 96

COMPETITION 97

Trade Association97

BIA 97

Company Intelligence 97

Angel Biotechnology97

Argenta 97

Ark Therapeutics 98

Astex Therapeutics98

BigDNA98

BioFocus 98

Biogen Idec 98

BTG 99

Cellartis99

Convergence Pharmaceuticals 99

FMC BioPolymer 99

ImmuPharma 99

Intercell 99

Lonza 100

NovaBiotics100

Oxford BioMedica100

PolyTherics 100

Silence Therapeutics 101

UCB 101

Competitive Strategies 101

CONCLUSIONS: OPPORTUNITIES & CHALLENGES 103

Strategic Espicom Analysis 103

MACROENVIRONMENT 103

EPIDEMIOLOGY 103

HEALTHCARE103

REGULATORY AFFAIRS104

PRICING & REIMBURSEMENT 104

DISTRIBUTION CHANNELS 105

MARKET 105

COMPETITION 106

OTC PHARMACEUTICALS 106

GENERIC PHARMACEUTICALS106

BIOLOGICS & BIOSIMILARS 106

Radar Analysis 108

SWOT Analysis 108

DIRECTORY 109

GOVERNMENT ORGANISATIONS 109

PHARMACEUTICAL COMPANIES 109

Biologic Companies 109

Generic Companies 109

PHARMACEUTICAL DISTRIBUTORS110

PHARMACY CHAINS 110

TRADE ORGANISATIONS110

List of Tables

Espicom Analysis of the Pharmaceutical Market, 2012 2

Key Data Projections, 2012-2017 3

Political Landscape, 2012 4

Regional Ranking of Projected Economies, 2017 5

Projected Economy, 2012-2017 5

Regional Ranking of Projected Demographics, 2017 7

Projected Demographics, 2012-2017 7

Demographic Indicators, 2002-2009 8

Causes of Death by Country, 2010 9

HIV and AIDS Cases, up to 2010 10

Regional Ranking of Projected Health Expenditure, 2017 17

Projected Health Expenditure, 2012-201717

Inpatient Procedures and Interventions by Type, 2010/11 21

Regional Ranking of Projected Physicians, 2017 22

Projected Physicians, 2012-2017 22

Consultants by Specialty in England, 2008-2010 23

NHS Nurses by Country, 2007-2009 23

Patient Access Schemes in Published Guidance, 2007-2010 30

NICE Appraisals in Development, January 2012 31

Members of BAPW, 2011 34

Celesio's Revenue from Wholesale Activities, 2007-2009 (Euro Millions) 35

Alliance Healthcare's Financial Highlights, 2008-2010 (£ Millions) 35

Regional Ranking of Projected Pharmaceutical Markets, 2017 38

Projected Pharmaceutical Market at Retail Prices, 2012-2017 38

Historical Pharmaceutical Market at Retail Prices, 1995-2011 40

Written Prescriptions, 2006-2010 (Millions) 41

Prescriptions by Value, 2006-2010 (£ Millions) 41

Prescriptions & Cost by Therapeutic Area in the UK, 2010 42

Prescriptions & Cost by Therapeutic Area in England, 2010 43

Top 20 Prescribed Drugs in England by Value, 2010 44

Top 20 Prescribed Drugs in England by Volume, 2010 45

Cost of Pharmaceuticals Issued by Hospital Pharmacies in England, 2003-2010 (£ Millions) 45

Prescriptions & Cost by Therapeutic Area in Wales, 2010 46

Prescriptions & Cost by Therapeutic Area in Scotland, 2010 47

Prescriptions & Cost by Therapeutic Area in Northern Ireland, 201048

Pharmaceutical R&D Expenditure, 1972-2007 (£ Millions) 50

Pharmaceutical Production, 1995-2010 (Euros 000s) 52

Pharmaceutical Exports by Category, 1995-2010 (US$000s) 53

Pharmaceutical Exports by Country/Region, 2010 (US$000s) 55

Pharmaceutical Imports by Category, 1995-2010 (US$000s) 56

Imports of Raw Materials by Country/Region, 2010 (US$000s) 58

Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s) 58

Imports of Medicaments by Country/Region, 2010 (US$000s) 59

Balance of Pharmaceutical Trade, 1995-2010 (US$000s) 60

Full Members of the ABPI, 2011 61

AstraZeneca's Principal Operating Results, 2006-2010 (US$ Million) 66

AstraZeneca's Sales by Geographic Area, 2006-2010 (US$ Million) 67

AstraZeneca's Sales by Leading Products, 2006-2010 (US$ Million)68

AstraZeneca's Recent Product Approvals, 2010-2011 69

AstraZeneca's Major Manufacturing Facilities by Location, 2011 71

GSK's Principal Operating Results, 2006-2010 (£ Million) 73

GSK's Sales by Geographic Area, 2007-2010 (£ Million) 73

GSK's Sales by Leading Products, 2006-2010 (£ Million) 74

GSK's Recent Product Approvals, 2010-2011 75 Shire's Principal Operating Results, 2006-2010 (US$ Million) 78

Shire's Revenue by Business Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Geographic Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Leading Products, 2006-2010 (US$ Million) 79

Shire's Recent Product Approvals, 2010-2011 80

Shire's Major Manufacturing Facilities by Location, 2011 81

OTC Sales at Retail Prices, 2007-2010 (£ Millions) 83

Full Members of PAGB, 2011 84

Prescriptions Written and Dispensed Generically in England by Value, 1996-2010 (£ Millions) 87

Prescriptions Written and Dispensed Generically in England by Volume, 1996-2010 (Millions) 88

Generic Prescribing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 88

Generic Dispensing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 89

Members of BGMA, 2011 90

Biosimilars Approved in the EU 95

Espicom Analysis of the Pharmaceutical Market, 2012 107

SWOT Analysis of the Pharmaceutical Market, 2012 108

List of Charts

Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail Prices, 2017 39

Regional Comparison of Projected Pharmaceutical Market Share, 2017 39

Historical Pharmaceutical Market at Retail Prices, 1995-201140

Pharmaceutical Exports, 1995-2010 (US$ Billions) 54

Pharmaceutical Exports by Country/Region, 2010 (%) 54

Pharmaceutical Imports, 1995-2010 (US$ Billions) 56

Imports of Pharmaceuticals by Country/Region, 2010 (%) 57

Balance of Pharmaceutical Trade, 1995-2010 (US$ Billions)60

Radar Graph of the Pharmaceutical Market, 2012 108

To order this report:

Pharmaceutical Industry: The Pharmaceutical Market: UK

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for s...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, discussed how VPaaS enables you to move fast, creating scalable video experiences that reach your aud...